Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 108-112

  Liang, Matthew H ^a,b,c,d,f   Simard, Julia F ^d   Costenbader, Karen ^a,b   Dore, Benjamin T ^a   Ward, Michael ^e   Fortin, Paul R ^g   Illei, Gabor G ^e   Manzi, Susan ^h   Mittleman, Barbara ⁱ   Buyon, Jill ^j   Gupta, Samardeep ^a,f   Abrahamowicz, Michal ^k  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Robert B Brigham Arthritis and Musculoskeletal Diseases Clinical Research Center   (United States)

^c Center for Advanced Methodological Support for SLE Clinical Trials (ASSIST)   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e National Institute of Arthritis and Musculoskeletal and Skin Disease   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j NEW YORK UNIVERSITY   (United States)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PHENOTYPE; SCREENING; SIMULATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VALIDATION PROCESS; VALIDATION STUDY; COMPUTER SIMULATION;

BIOLOGICAL MARKERS; COMPUTER SIMULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 65549161447     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009787582388     Document Type: Article

References (22)

1. Illei, G.G.; Tackey, E.; Lapteva, L. and Lipsky, P.E. (2004) Biomarkers in systemic lupus erythematosus I. General overview of biomarkers and their applicability. Arthritis Rheum., 50, 1709-1720.
2. Illei, G.G.; Tackey, E.; Lapteva, L. and Lipsky, P.E. (2004) Biomarkers in systemic lupus erythematosus II. markers of disease activity. Arthritis Rheum., 50, 2048-2065.
3. Firestein, G.S. (2006) A Biomarker by any other name. Nat. Clin. Pract. Rheumatol., 2, 635.
4. Frank, R. and Hargreaves, R. (2003) Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov., 2, 566-580.
5. Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin. Pharmacol. Ther., 69, 89-95.
6. Fleming, T.R.; Prentice, R.L.; Pepe, M.S. and Glidden, D. (1994) Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat. Med., 13, 955-968.
7. Prentice, R.L. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med., 8, 431-440.
8. Lesko, L.J. and Atkinson, A.J.Jr. (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol., 41, 347-366.
9. Wood, A.J J. (2006)A proposal for radical changes in the drug-approval process. N. Eng. J. Med., 355, 618-623.
10. ACR Ad Hoc Committee on Response Criteria. (2004) The american college of rheumatology response criteria for systemic lupus erythematosus clinical trials: overall disease activity. Arthritis Rheum., 50, 3418-3426.
11. Braggio, S.; Barnaby, R.J.; Grossi, P. and Cugola, M.A. (1996) strategy for validation of bioanalyticalMethods. J. Pharm. Biomed. Anal., 14, 375-388.
12. Buick, A.R.; Doig, M.V.; Jeal, S.C.; Land, G.S. and McDowall, R.D. (1990) Method validation in the bioanalytical laboratory. J. Pharm. Biomed. Anal., 8, 629-637
13. Findlay, J.W.; Smith, W.C.; Lee, J.W.; Nordblom, G.D.; Das, I.; DeSilva, B.S.; Khan, M.N. and Bowsher, R.R. (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal., 21, 1249-1273.
14. Buyse, M. and Molenberghs, G. (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics, 54, 1014-1029.
15. Weir, C.J. and Walley, R.J. (2006) Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat. Med., 25, 183-203.
16. Esdaile, J.M.; Abrahamowicz, M.; Joseph, L.; MacKenzie, T.; Li, Y. and Danoff, D. (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum., 39, 370-378.
17. Liang, M.H. and Simard, J.F. (2006) The large print giveth; the small print taketh away: Pre-emptive treatment of serologically active, clinically quiet SLE. Arthritis Rheum., 54, 3378-3380.
18. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on SLE Response Criteria. (2006) The american college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum., 54, 421-432.
19. Kalbfleisch, J.D. and Prentice, R.L. (1980) The statistical analysis of failure time data, Wiley and Sons, New York.
20. Leffondre, K.; Abrahamowicz, M. and Siemiatycki, J. (2003) Evaluation of Cox's model and logistic regression for matched case-control data with time-dependent covariates: a simulation study. Stat. Med., 22, 3781-3794.
21. Abrahamowicz, M.; du Berger, R.; Esdaile, J.M.; Fortin, P.R. and Liang, M.H. (2006) Selected methodological issues in validation of biomarkers of latent disease activity. Proceedings of the 27th annual meeting of the international society for clinical biostatistics, Geneva, Switzerland.
22. Zhou, Z.; Rahme, E.; Abrahamowicz, M. and Pilote, L. (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods. Am. J. Epidemiol., 162, 1016-1023.